Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Details:
RBX2660 is an investigational microbiota-based live biotherapeutic studied for its potential to reduce recurrent C. difficile infection after antibiotic treatment.
Lead Product(s): Rbx2660
Therapeutic Area: Infections and Infectious Diseases Product Name: RBX2660
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 09, 2022
Details:
Zevtera (ceftobiprole) was well tolerated and the observed safety profile was consistent with previous phase 3 studies and the post-marketing experience with ceftobiprole. In the ERADICATE study the overall rate of adverse events was similar between the two treatment groups.
Lead Product(s): Ceftobiprole Medocaril
Therapeutic Area: Infections and Infectious Diseases Product Name: Zevtera
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2022
Details:
Two of these abstracts reviewed data from PUNCH™ CD clinical program and included subgroup analyses on the potential of RBX2660 to reduce CDI recurrence consistently and safely in adults regardless of their baseline characteristics.
Lead Product(s): Rbx2660
Therapeutic Area: Infections and Infectious Diseases Product Name: RBX2660
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2022
Details:
RBX2660 is a potential first-in-class microbiota-based live biotherapeutic studied to deliver a broad consortium of diverse microbes to the gut to reduce recurrent C. difficile infection after antibiotic treatment.
Lead Product(s): Rbx2660
Therapeutic Area: Infections and Infectious Diseases Product Name: RBX2660
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2022
Details:
Laboratory studies using full Omicron pseudovirus confirm MP0420 (ensovibep), maintains ability to neutralize the variant with very high potency, relative to substantial reductions in neutralizing potency across numerous anti-SARS-CoV-2 antibody drugs.
Lead Product(s): Ensovibep,Remdesivir,Sotrovimab
Therapeutic Area: Infections and Infectious Diseases Product Name: MP0420
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2021
Details:
Under the terms of license agreement between Pfizer and MPP, qualified generic medicine manufacturers worldwide that are granted sub-licenses will be able to supply PF-07321332 in combination with ritonavir to 95 countries, covering up to approx 53% of the world’s population.
Lead Product(s): Nirmatrelvir,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Paxlovid
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 16, 2021
Details:
Under the terms of the agreement, MPP, through the license granted by Merck, will be permitted to further license non-exclusive sublicenses to manufacturers and diversify the manufacturing base or WHO-prequalified molnupiravir to countries covered by the MPP License.
Lead Product(s): Molnupiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: EIDD-2801
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co. Inc.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 27, 2021
Details:
RBX2660 is a potential first-in-class microbiota-based live biotherapeutic being studied to deliver a broad consortium of diverse microbes to the gut to reduce recurrent C. difficile infection.
Lead Product(s): Rbx2660
Therapeutic Area: Infections and Infectious Diseases Product Name: RBX2660
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2021
Details:
A new analysis of Phase 3 data also revealed among responders to treatment that RBX2660 significantly increased the amount of gut bacteria associated with health and decreased that of gut bacteria associated with CDI disease.
Lead Product(s): Rbx2660
Therapeutic Area: Infections and Infectious Diseases Product Name: RBX2660
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2021
Details:
RBX2660 demonstrated an increase in the relative abundance of two important classes of beneficial bacteria – Bacteroidia and Clostridia – and reduced relative abundance of classes that could be considered harmful, Gammaproteobacteria and Bacilli.
Lead Product(s): Rbx2660
Therapeutic Area: Infections and Infectious Diseases Product Name: RBX2660
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2021
